HS-20093 + anlotinib

HS-20093 + anlotinib is an investigational combination therapy under clinical evaluation, primarily for advanced solid tumors including bone and soft tissue sarcoma, non-small cell lung cancer (NSCLC), and small cell lung cancer. HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3 (CD276), a protein widely expressed in various tumors. It consists of a monoclonal antibody covalently linked to a topoisomerase inhibitor payload, designed to deliver cytotoxic activity selectively to tumor cells expressing B7-H3. Anlotinib is an orally administered multi-targeted small molecule receptor tyrosine kinase inhibitor, acting on VEGFR, FGFR, PDGFR, and c-Kit, thereby inhibiting angiogenesis and tumor proliferation. The combined use is intended to potentiate anti-tumor effects through both direct cytotoxic and anti-angiogenic mechanisms, with current studies focused on safety, tolerability, pharmacokinetics, and anti-tumor activity in refractory or advanced sarcoma and other solid tumors[1][2][5][8].

Other names

HS-20093 and anlotinibHS20093 and anlotinibHS 20093 and anlotinibHS20093 + anlotinib